Eric Bernabei Joins Avellino Labs as Chief Sales and Marketing Officer
Avellino Labs announced that Eric Bernabei has joined the company as chief sales and marketing officer. Mr. Bernabei, who brings more than 20 years of clinical and commercial ophthalmic experience to the role, will inform and implement the strategic expansion of Avellino Labs’ disruptive genetic diagnostic and therapeutic technologies in support of the company’s global leadership in the genetics and ophthalmic sectors.
Mr. Bernabei joins Avellino Labs after his most recent roles as global product and strategic marketing director with Alcon. Throughout his career, Mr. Bernabei has focused on introducing new and advanced eye care technologies in various global, regional and country level leadership roles. With his global experience and relationships with ophthalmic thought leaders, Mr. Bernabei will help translate the value of Avellino’s genomic technology to clinicians and shape market adoption.
“Eric truly understands what is driving the success of Avellino Labs in our best markets like Korea, and he will put the right partnerships and strategies in place to guide our growth in U.S. and European markets,” Avellino Labs chairman of the board Gene Lee said in the news release. “His trusted expertise has made a tremendous impact on the advancement of several innovative ophthalmic technologies around the globe, which will be important to Avellino moving forward.”
In his new role, Mr. Bernabei’s immediate focus will be the development of a strategic marketing program focused on the growth of Avellino Labs’ expanding genetic service offerings and has tapped leading specialty marketing firm HCB Health to support the initiative.
Before joining Avellino Labs, Mr. Bernabei actively managed multinational marketing and sales initiatives for medical device and pharmaceutical organizations, including extended in-market assignments in Asia and Europe for Alcon following clinical support roles at Becton Dickinson and Summit Technology.
“I have been very fortunate to have been involved in the launch of some transformative cataract and refractive technologies and look forward to changing how doctors approach the diagnosis and treatment of disease in ophthalmology with Avellino,” Mr. Bernabei said in the news release. “Our goal is to identify the best way to bring personalized medicine into each country and culture, uncover what resonates deepest with physicians and patients, and leverage Avellino’s genetic testing and therapeutics to address the global unmet needs in ophthalmology.”